The startup develops a therapeutic ablation catheter that integrates optical technology for real-time lesion and gap detection during cardiac procedures. This enables electrophysiologists to assess tissue composition and metabolic activity, improving clinical outcomes and minimizing the need for repeat ablations.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiac ablation procedures can be limited by the inability to precisely assess tissue composition and lesion formation in real-time, potentially leading to incomplete ablations and the need for repeat procedures. Current methods lack the ability to provide immediate feedback on tissue characteristics and the effectiveness of the ablation during the procedure.
Solution
The company is developing a therapeutic ablation catheter that incorporates optical coherence tomography (OCT) and other optical technologies to provide electrophysiologists with real-time feedback on tissue characteristics and lesion formation during cardiac ablation procedures. The integrated optical system allows for the assessment of tissue composition, metabolic activity, and lesion depth, enabling physicians to optimize ablation parameters and ensure complete lesion formation. By providing immediate feedback, the catheter aims to improve clinical outcomes, reduce the need for repeat ablations, and enhance the overall efficiency of cardiac ablation procedures.
Target Audience
The primary target audience includes electrophysiologists and hospitals performing cardiac ablation procedures for the treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.
Features
- Integrated optical coherence tomography (OCT) for real-time, high-resolution imaging of cardiac tissue
- Spectroscopic analysis to assess tissue composition and metabolic activity
- Real-time lesion detection and gap assessment during ablation
- Steerable catheter design for precise navigation and targeting of ablation sites
- Compatibility with existing ablation generators and mapping systems